Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Brodalumab (AMG 827) in Moderate-to-Severe Psoriasis
NCT00975637Phase 2Completed
- Sponsor
- Valeant Pharmaceuticals
- Start
- Dec 2009
- Primary completion
- Jul 2010
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of brodalumab in plaque psoriasis, sponsored by Valeant Pharmaceuticals. Started Dec 2009; status: completed.
02
Drugs
brodalumab
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT00975637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00975637.